PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Department of Biochemistry, University of Washington, Seattle, WA 98195, USA.\', \'Institut Pasteur and CNRS UMR 3569, Unité de Virologie Structurale, Paris, France.\', \'Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.\', \'Vir Biotechnology, San Francisco, CA 94158, USA.\', \'Departments of Medicine, Molecular Microbiology, Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA.\', \'Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, KU Leuven, Belgium.\', \'III Division of Infectious Diseases, Luigi Sacco University Hospital, University of Milan, Italy.\', \'Washington University School of Medicine, St. Louis, MO, USA.\', \'UTSouthwestern Medical Center, Dallas, TX, USA.\', \'Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. dveesler@uw.edu katja.fink@alumni.ethz.ch.\', \'Department of Biochemistry, University of Washington, Seattle, WA 98195, USA. dveesler@uw.edu katja.fink@alumni.ethz.ch.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • 10.1126/science.abe3354
?:hasPublicationType
?:journal
  • Science (New York, N.Y.)
is ?:pmid of
?:pmid
?:pmid
  • 32972994
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • -1.0
?:rankingScore_hIndex
  • -1
?:title
  • Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms.
?:type
?:year
  • 2020

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/32972994>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/32972994>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all